Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 1
2009 1
2010 5
2011 5
2012 10
2013 11
2014 21
2015 36
2016 33
2017 42
2018 44
2019 46
2020 44
2021 54
2022 50
2023 33
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Results by year

Filters applied: . Clear all
Page 1
Dual-phase [18F]florbetapir in frontotemporal dementia.
Asghar M, Hinz R, Herholz K, Carter SF. Asghar M, et al. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):304-311. doi: 10.1007/s00259-018-4238-2. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569187 Free PMC article.
PURPOSE: The PET tracer [18F]florbetapir is a specific fibrillar amyloid-beta (Abeta) biomarker. ...METHODS: Eight bvFTD patients underwent [18F]florbetapir and [18]FDG-PET scans. Additionally, ten healthy controls and ten AD patients underwent flor …
PURPOSE: The PET tracer [18F]florbetapir is a specific fibrillar amyloid-beta (Abeta) biomarker. ...METHODS: Eight bvFTD patie …
Florbetapir F 18.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Aug 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999779 Free Books & Documents. Review.
Information in this record refers to the use of florbetapir 18 as a diagnostic agent. No information is available on the use of florbetapir 18 during breastfeeding. ...
Information in this record refers to the use of florbetapir 18 as a diagnostic agent. No information is available on the use of fl …
Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N, Yanai K. Okamura N, et al. IDrugs. 2010 Dec;13(12):890-9. IDrugs. 2010. PMID: 21154149 Review.
Florbetapir (18F), being developed by Avid Radiopharmaceuticals, is an 18F-labeled PET tracer binding to amyloid-beta (Abeta) plaques for the potential detection of Alzheimer's disease (AD). ...No serious adverse events were reported in any of the clinical tr …
Florbetapir (18F), being developed by Avid Radiopharmaceuticals, is an 18F-labeled PET tracer binding to amyloid-beta ( …
18F-Florbetapir PET in Primary Cerebral Amyloidoma.
Soffers F, Ceyssens S, Buffet W, de Surgeloose D, Crols R. Soffers F, et al. Clin Nucl Med. 2020 Oct;45(10):838-839. doi: 10.1097/RLU.0000000000003214. Clin Nucl Med. 2020. PMID: 32796236
Pathological investigation revealed AL (lambda) amyloidoma. F-florbetapir PET/CT was used to support the diagnosis and in follow-up. This case highlights that F-florbetapir PET/CT might play a role in the diagnostic workup of patients suggestive of cerebral amyloido …
Pathological investigation revealed AL (lambda) amyloidoma. F-florbetapir PET/CT was used to support the diagnosis and in follow-up. …
[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis.
Lilleker JB, Hodgson R, Roberts M, Herholz K, Howard J, Hinz R, Chinoy H. Lilleker JB, et al. Ann Rheum Dis. 2019 May;78(5):657-662. doi: 10.1136/annrheumdis-2018-214644. Epub 2019 Feb 13. Ann Rheum Dis. 2019. PMID: 30760470 Free PMC article.
RESULTS: [18F]florbetapir standardised uptake value ratios were significantly higher in those with IBM compared with PM for all assessed regions (total-[18F]florbetapir standardised uptake value ratio 1.45 (1.28 to 2.05) vs 1.01 (0.80 to 1.22), p=0.005 …
RESULTS: [18F]florbetapir standardised uptake value ratios were significantly higher in those with IBM compared with PM for al …
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G, Vernooij RW, Fuentes Padilla P, Zamora J, Bonfill Cosp X, Flicker L. Martínez G, et al. Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2. Cochrane Database Syst Rev. 2017. PMID: 29164603 Free PMC article. Review.
However, the DTA of (18)F-florbetapir to predict the progression from MCI to Alzheimer's disease dementia (ADD) or other dementias has not yet been systematically evaluated. OBJECTIVES: To determine the DTA of the (18)F-florbetapir PET scan for detecting people with …
However, the DTA of (18)F-florbetapir to predict the progression from MCI to Alzheimer's disease dementia (ADD) or other dementias ha …
Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Trembath L, Newell M, Devous MD Sr. Trembath L, et al. J Nucl Med Technol. 2015 Sep;43(3):175-84. doi: 10.2967/jnmt.115.156679. Epub 2015 Aug 13. J Nucl Med Technol. 2015. PMID: 26271806 Free article. Review.
The focus of tracer-specific information will be on (18)F-florbetapir (indications, contraindications, dosing, administration, uptake time, scanning time, acquisition, processing, biodistribution, radiation dose, adverse events, and display). ...
The focus of tracer-specific information will be on (18)F-florbetapir (indications, contraindications, dosing, administration, uptake …
Amyloid-β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis.
Ruan D, Sun L. Ruan D, et al. Brain Behav. 2023 Jan;13(1):e2850. doi: 10.1002/brb3.2850. Epub 2022 Dec 27. Brain Behav. 2023. PMID: 36573329 Free PMC article. Review.
The differences in diagnostic efficacy between visual assessment and quantitative analysis and between (11) C-PIB PET and (18) F-florbetapir PET were insignificant. CONCLUSIONS: The overall performance of Abeta PET in diagnosing AD is favorable, but the differentiation bet …
The differences in diagnostic efficacy between visual assessment and quantitative analysis and between (11) C-PIB PET and (18) F-florbeta …
18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, Haense C, Richardson AM, Gerhard A, Anton-Rodriguez JM, Snowden JS, Neary D, Pontecorvo MJ, Herholz K. Kobylecki C, et al. J Nucl Med. 2015 Mar;56(3):386-91. doi: 10.2967/jnumed.114.147454. Epub 2015 Feb 5. J Nucl Med. 2015. PMID: 25655625 Free article.
Static PET images were evaluated by trained raters masked to clinical status and regional analysis. RESULTS: Total cortical gray matter (18)F-florbetapir uptake values were significantly higher in AD patients (median SUVR, 1.73) than FTD patients (SUVR, 1.13, P = 0.002) an …
Static PET images were evaluated by trained raters masked to clinical status and regional analysis. RESULTS: Total cortical gray matter (18) …
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, Karikari TK, Lantero-Rodriguez J, Brum WS, Lussier FZ, Bezgin G, Stevenson J, Rahmouni N, Kunach P, Wang YT, Fernandez-Arias J, Socualaya KQ, Macedo AC, Ferrari-Souza JP, Ferreira PCL, Bellaver B, Leffa DT, Zimmer ER, Vitali P, Soucy JP, Triana-Baltzer G, Kolb HC, Pascoal TA, Saha-Chaudhuri P, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P. Therriault J, et al. JAMA Neurol. 2023 Feb 1;80(2):188-199. doi: 10.1001/jamaneurol.2022.4485. JAMA Neurol. 2023. PMID: 36508198 Free PMC article.
The first TRIAD subsample comprised individuals assessed with CSF p-tau (p-tau181, p-tau217, p-tau231, p-tau235), [18F]AZD4694 amyloid PET, and [18F]MK6240 tau PET. The second TRIAD subsample included individuals assessed with plasma p-tau (p-tau181, p-tau217, p-tau …
The first TRIAD subsample comprised individuals assessed with CSF p-tau (p-tau181, p-tau217, p-tau231, p-tau235), [18F]AZD4694 amyloi …
380 results